Some two thirds of Swiss medtech companies support the new Switzerland-EU package. This is the result of a survey conducted by the opinion research institute JRC. Approval has also increased since the announcement of the US tariffs. +Get the most important news from Switzerland in your inbox According to the survey, over 70% of companies rate the package as important for their business and 80% as crucial for Switzerland as a medtech location. Furthermore, eight out of ten companies support the bilateral approach to date, according to the Swiss Medical Technology Association Swiss Medtech on Friday. The decisive factors for this support are the free movement of persons and direct market access, according to the press release from the industry association, which commissioned the survey. Swiss Medtech sees this approval as a “clear mandate to support the Bilaterals III with commitment in the interests of the medtech sector”. During the survey period, US President Trump announced the ...
